Financials data is unavailable for this security.
View more
Year on year Sansure Biotech Inc 's revenues fell -84.39% from 6.45bn to 1.01bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 1.94bn to 363.72m, a -81.22% decrease.
| Gross margin | 76.43% |
|---|---|
| Net profit margin | 15.12% |
| Operating margin | 19.17% |
| Return on assets | 2.52% |
|---|---|
| Return on equity | 3.54% |
| Return on investment | 2.79% |
More ▼
Cash flow in CNYView more
In 2023, Sansure Biotech Inc increased its cash reserves by 34.61%, or 1.07bn. Cash Flow from Investing totalled 1.40bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 43.54m in cash from operations while cash used for financing totalled 369.11m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 12.62 |
|---|---|
| Tangible book value per share | 11.86 |
More ▼
Balance sheet in CNYView more
| Current ratio | 8.04 |
|---|---|
| Quick ratio | 7.45 |
| Total debt/total equity | 0.0629 |
|---|---|
| Total debt/total capital | 0.0583 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -64.39% and -81.27%, respectively. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 157.33% |
| EPS growth(5 years) | 76.96 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -58.16 |
More ▼
